RxDoctor Payments Data

Alexa Skibitski, PA

Physician Assistant · East Syracuse, NYNPI 1821604182

Payments from drug & device makers

$3,125in general payments, 2019–2025

Across 41 payments — averaging $76.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pharmacyclics LLC, An Abbvie Company$430
  • E.r. Squibb & Sons, L.L.C.$300
  • Seagen Inc.$224
  • Amgen$192
  • GSK$189
  • AbbVie$166
  • plus $2K from 20 others

What the payments were for

  • Food & beverage$2,60683%
  • Education$52017%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,125 in reported general payments places this provider in the 90th percentile of 11,358 physician assistant providers in New York.

See all physician assistant providers in New York

Medicare billing

Part B allowed, 2024
$246,271
Medicare patients
251
Services billed
17,239

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ImbruvicaIbrutinib20$304,788
BrukinsaZanubrutinib21$301,445
RevlimidLenalidomide14$284,776
CalquenceAcalabrutinib Maleate24$241,898
Lenalidomide16$222,476
IbrancePalbociclib16$221,819
PromactaEltrombopag Olamine16$179,413
JakafiRuxolitinib Phosphate14$176,423
VenclextaVenetoclax14$103,683
EliquisApixaban69$46,348
XareltoRivaroxaban35$29,235
Exemestane19$4,795
Fentanyl49$3,973
ValacyclovirValacyclovir Hcl66$2,770
Hydroxyurea85$2,058

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Pharmacyclics LLC, An Abbvie CompanyImbruvica$430$304,78820 claims
PfizerIbrance, Eliquis$100$268,16785 claims
AstraZenecaCalquence$70$241,89824 claims
Incyte CorporationJakafi$100$176,42314 claims
AbbVieVenclexta$166$103,68314 claims
Johnson & JohnsonXarelto$70$29,23535 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 11,358 physician assistant providers in New York.

Other physician assistant in East Syracuse

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →